ScreenerHero

ATX Amplia Therapeutics Limited

ASX · AU · Healthcare · Biotechnology · ampliatx.com
—Mkt Cap: —P/E: —

Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotin…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.87BUSDP/E 29.6
MRNA
Moderna, Inc.
$94.42BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$81.99BUSDP/E 19.1
ARGX
argenx SE
$53.47BUSDP/E 32.5
ARGX
argenx SE
$53.22BUSDP/E 31.6
UCB
UCB SA
$44.02BUSDP/E 17.8
ONC
BeOne Medicines AG
$42.56BUSDP/E 66.4
RVMD
Revolution Medicines, Inc.
$40.57BUSD
RPRX
Royalty Pharma plc
$34.45BUSDP/E 30.4
ALNY
Alnylam Pharmaceuticals, Inc.
$31.32BUSDP/E 39.3
ROIV
Roivant Sciences Ltd.
$24.59BUSD
GMAB
Genmab A/S
$23.32BUSDP/E 31.7
GMAB
Genmab A/S
$23.26BUSDP/E 29.8
INCY
Incyte Corporation
$22.96BUSDP/E 14.0
BNTX
BioNTech SE
$22.66BUSD
INSM
Insmed Incorporated
$21.67BUSD
EXEL
Exelixis, Inc.
$15.57BUSDP/E 19.3
ASND
Ascendis Pharma A/S
$14.91BUSDP/E 17.4
JAZZ
Jazz Pharmaceuticals plc
$13.92BUSDP/E 14.7
HALO
Halozyme Therapeutics, Inc.
$13.79BUSDP/E 33.4

Key Statistics

Company
Market Cap—
Enterprise Value16.44M USD
Revenue (TTM)3.31M USD
Gross Profit3.04M USD
Net Income (TTM)-5.33M USD
Revenue/Share0.01 AUD
Last Price—
Fiscal Year EndMar 2026
MR QuarterMar 2026
Employees—
CountryAU
SectorHealthcare
IndustryBiotechnology
ISINAU0000023822
Valuation
P/E (Trailing)—
P/E (Forward)-14.29
PEG—
EV/EBITDA-2.84
EV/Revenue4.97
P/S10.71
P/B1.30
EPS (TTM)-0.02
EPS (Forward)-0.01
52W Range
—
52W High—
52W Low—
Profitability
Gross Margin91.95%
Oper. Margin-185.70%
EBITDA Margin-174.80%
Profit Margin-160.86%
ROE-19.53%
ROA-18.60%
Growth
Revenue Growth-9.10%
Earnings Growth—
Cash Flow & Leverage
Operating CF-6.04M USD
CapEx (TTM)23.01K USD
FCF Margin-135.29%
FCF Yield—
Net Debt-19.01M USD
Net Debt/EBITDA3.29
Balance Sheet
Debt/Equity0.01
Current Ratio19.78
Quick Ratio19.54
Book Value/Sh0.08 AUD
Cash/Share0.05 AUD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 AUD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateApr 30, 2018
Analyst Consensus
Rating—
Target (Mean)0.4200 AUD
Target Range0.4200 AUD – 0.4200 AUD
# Analysts1
Ownership
Shares Out.513.31M
Float414.17M
Insiders9.56%
Institutions23.04%
Technical
SMA 500.1282 AUD
SMA 2000.1387 AUD
Beta-0.33
S&P 52W Chg16.44%
Avg Vol (30d)—
Avg Vol (10d)339.67K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—